Home » Newsletters » BioWorld Science

BioWorld Science

March 13, 2014

View Archived Issues

Lung adenocarcinoma subtype correlates with KRAS, EGFR and ERBB2 gene mutations

Plexcera Therapeutics gives details on development of recombinant human acid ceramidase

Stem cells from subjects with Alzheimer's disease mutation APP V717I analyzed

Tocagen doses first patient in trial of TOCA-511 and TOCA-FC

First patient enrolled in study of triheptanoin in GLUT-1 deficiency syndrome

Roche synthesizes dual FABP inhibitors

Ventana Medical Systems and Bayer extend companion diagnostics collaboration

MTL-005 demonstrates radiosensitizing effects in mouse models of squamous cell carcinoma

Grespo presents lead compound for mild cognitive impairment

Safety monitoring board issues positive assessment of phase IIb TNF-Kinoid trial

Fate Therapeutics begins phase II trial of ProHema for hematologic malignancies

Upsher-Smith Laboratories receives FDA approval for Qudexy XR

Viamet reports interim data from phase II study of VT-1161

Pharmascience divulges novel BTK inhibitors

FDA approves Mallinckrodt's Xartemis XR

Novel H3R ligands disclosed by Suven Life Sciences

N30 Pharmaceuticals begins phase I trial of N-91115 for cystic fibrosis

Suzhou Zelgen Biosciences discloses novel coagulation factor Xa inhibitors

FDA places imetelstat on clinical hold

Lubiprostone not approved in the U.K. for opioid-induced constipation

World Kidney Day: Early diagnosis and more accessible solutions for chronic kidney disease

New U.K. phase II study investigates olaparib for NSCLC

Genexine plans Korean study of GX-051 for advanced head and neck cancer

New study investigates riociguat in PAH patients with insufficient response to PDE5 inhibitors

Taigexyn approved in Taiwan for CAP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...